{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Cancer%2C+Squamous+Cell", "query": { "condition": "Skin Cancer, Squamous Cell" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 528, "total_pages": 53, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Cancer%2C+Squamous+Cell&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T03:24:24.033Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03901573", "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Merkel Cell Carcinoma", "Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "NT-I7", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2019-12-26", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 8, "location_summary": "Duarte, California • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03901573" }, { "nct_id": "NCT05551117", "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine 2.0 mg (Arm A)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine 2.7 mg (Arm B)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-06-13", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 14, "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551117" }, { "nct_id": "NCT07228442", "title": "L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Cutaneous Squamous Cell Carcinoma" ], "interventions": [ { "name": "L19IL2/L19TNF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philogen S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-09", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 6, "location_summary": "Orange, California • Atlanta, Georgia • Boston, Massachusetts + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07228442" }, { "nct_id": "NCT04339062", "title": "Cemiplimab in AlloSCT/SOT Recipients With CSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "Advanced Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-11-03", "completion_date": "2025-03-01", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04339062" }, { "nct_id": "NCT06992427", "title": "High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Gabapentin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Chemotheraphy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Analgesic Agent", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2025-06-05", "completion_date": "2031-04-15", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 200, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992427" }, { "nct_id": "NCT02452424", "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Gastrointestinal Stromal Tumor (GIST)", "Ovarian Cancer" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-07-02", "completion_date": "2018-10-12", "has_results": true, "last_update_posted_date": "2020-03-05", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02452424" }, { "nct_id": "NCT05902988", "title": "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "High Grade Serous Adenocarcinoma of Ovary", "Squamous Non-small-cell Lung Cancer", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Carcinosarcoma", "Uterine Carcinosarcoma", "Uterine Serous Carcinoma", "Endometrium Cancer", "Chromosomal Instability" ], "interventions": [ { "name": "VLS-1488", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-10-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902988" }, { "nct_id": "NCT00023790", "title": "Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Lymphoma", "Metastatic Cancer", "Non-melanomatous Skin Cancer", "Sarcoma" ], "interventions": [ { "name": "silicon phthalocyanine 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2001-08", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2011-08-24", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023790" }, { "nct_id": "NCT04424641", "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumor(s)", "Prostate Cancer", "Esophageal Cancer", "Triple Negative Breast Cancer (TNBC)", "Squamous Cell Carcinoma of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC)", "Bladder Cancer", "Uterine Cancer" ], "interventions": [ { "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2020-07-15", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04424641" }, { "nct_id": "NCT03894618", "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Melanoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Squamous Cell Carcinoma of the Anus", "Squamous Cell Carcinoma of the Cervix", "Squamous Cell Carcinoma of the Skin", "Renal Cell Carcinoma", "Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Mismatch Repair Deficient or MSI-High Solid Tumors" ], "interventions": [ { "name": "SL-279252", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shattuck Labs, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2019-03-26", "completion_date": "2023-05-04", "has_results": true, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-07-23T03:24:24.033Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894618" } ] }